跳至主要内容
临床试验/NL-OMON47474
NL-OMON47474已完成不适用

DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A. - DAVID

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
12 至 99(—)

入选标准

  • - Non-severe hemophilia A patients (FVIII equal to or higher than 0.01 IU/mL)
  • - In need of surgery or suffering from bleeding
  • - Age minimally 12 and maximally 70 years at study inclusion date
  • - Need for clotting factor concentrates; perioperatively, or around a bleeding
  • - Treatment duration with FVIII-concentrates of at least 48 hours
  • - Results of FVIII levels after a DDAVP test dose, or if test results are not
  • available, willingness to undergo a DDAVP test
  • - Male gender
  • - (Parental) informed consent

排除标准

  • - Patients with other congenital or acquired hemostatic abnormalities
  • - Very low response to DDAVP after 1 hour * absolute increase in FVIII < 0.2
  • - Clinically relevant FVIII inhibiting antibodies (>0.5 BU) in medical history
  • or preoperatively, unless successfully treated with immunotolerance therapy
  • - Start of FVIII-concentrate treatment >24 hours ago
  • - Contraindications for DDAVP, e.g. cardiovascular disease (see the protocol,
  • appendix IV)
  • - Use of co-medication that has an interaction with DDAVP (see the protocol,
  • appendix IV)
  • - Intolerance to previous DDAVP administrations
  • - DDAVP not advisable due to the type of surgery/bleeding according to the
  • hematologist and/or surgeon

研究者

相似试验